Antitumor Activity of the Investigational Proteasome Inhibitor MLN9708 in Mouse Models of B-cell and Plasma Cell Malignancies
Authors:
- 30 November 2011
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 17 (23) , 7313-7323
Abstract
Purpose: The clinical success of the first-in-class proteasome inhibitor bortezomib (VELCADE) has validated the proteasome as a therapeutic target for treating human cancers. MLN9708 is an investigational proteasome inhibitor that, compared with bortezomib, has improved pharmacokinetics, pharmacodynamics, and antitumor activity in preclinical studies. Here, we focused on evaluating the in vivo activity of MLN2238 (the biologically active form of MLN9708) in a variety of mouse models of hematologic malignancies, including tumor xenograft models derived from a human lymphoma cell line and primary human lymphoma tissue, and genetically engineered mouse (GEM) models of plasma cell malignancies (PCM). Experimental Design: Both cell line–derived OCI-Ly10 and primary human lymphoma–derived PHTX22L xenograft models of diffuse large B-cell lymphoma were used to evaluate the pharmacodynamics and antitumor effects of MLN2238 and bortezomib. The iMycCα/Bcl-XL GEM model was used to assess their effects on de novo PCM and overall survival. The newly developed DP54-Luc–disseminated model of iMycCα/Bcl-XL was used to determine antitumor activity and effects on osteolytic bone disease. Results: MLN2238 has an improved pharmacodynamic profile and antitumor activity compared with bortezomib in both OCI-Ly10 and PHTX22L models. Although both MLN2238 and bortezomib prolonged overall survival, reduced splenomegaly, and attenuated IgG2a levels in the iMycCα/Bcl-XL GEM model, only MLN2238 alleviated osteolytic bone disease in the DP54-Luc model. Conclusions: Our results clearly showed the antitumor activity of MLN2238 in a variety of mouse models of B-cell lymphoma and PCM, supporting its clinical development. MLN9708 is being evaluated in multiple phase I and I/II trials. Clin Cancer Res; 17(23); 7313–23. ©2011 AACR.Keywords
All Related Versions
This publication has 31 references indexed in Scilit:
- Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphomaBlood, 2009
- Strain-dependent differences in susceptibility to lung cancer in inbred mice exposed to mainstream cigarette smokeCancer Letters, 2008
- Proteasome Inhibitors in Cancer Therapy: Lessons from the First DecadeClinical Cancer Research, 2008
- Dissociation of Epithelial and Neuroendocrine Carcinoma Lineages in the Transgenic Adenocarcinoma of Mouse Prostate Model of Prostate CancerThe American Journal of Pathology, 2008
- Cell-specific and efficient expression in mouse and human B cells by a novel hybrid immunoglobulin promoter in a lentiviral vectorGene Therapy, 2007
- Murine Models to Evaluate Novel and Conventional Therapeutic Strategies for CancerThe American Journal of Pathology, 2007
- Effects of FVB/NJ and C57Bl/6J strain backgrounds on mammary tumor phenotype in inducible nitric oxide synthase deficient miceTransgenic Research, 2007
- The Use of Targeted Mouse Models for Preclinical Testing of Novel Cancer TherapeuticsClinical Cancer Research, 2006
- Drug discovery in the ubiquitin–proteasome systemNature Reviews Drug Discovery, 2006
- Distinct types of diffuse large B-cell lymphoma identified by gene expression profilingNature, 2000